1 September 2024

Targeted DEP™ outperforms leading treatments in ovarian cancer model

Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that treatment with its novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model. 

Starpharma’s antibody-targeted DEP™ conjugate (using Herceptin as the targeting group) significantly outperformed both Roche’s Kadcyla® (T-DM1), a Herceptin® antibody-drug conjugate (ADC), and the monoclonal antibody Herceptin® (Trastuzumab) itself in the pre-clinical ovarian cancer model.

Download ASX Announcement: Targeted DEP outperforms leading treatments in ovarian cancer model (pdf file, 302kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.